These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 22007842)

  • 41. Neuroenhancing public health.
    Shaw D
    J Med Ethics; 2014 Jun; 40(6):389-91. PubMed ID: 23793059
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Neuroenhancement and mood enhancement – Physiological and pharmacodynamical background.
    Weiergräber M; Ehninger D; Broich K
    Med Monatsschr Pharm; 2017 Apr; 40(4):154-64. PubMed ID: 29952165
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Brain gain: the underground world of neuroenhancing drugs.
    Talbot M
    New Yorker; 2009 Apr; ():32-43. PubMed ID: 19399986
    [No Abstract]   [Full Text] [Related]  

  • 44. Rethinking the thinking cap: ethics of neural enhancement using noninvasive brain stimulation.
    Hamilton R; Messing S; Chatterjee A
    Neurology; 2011 Jan; 76(2):187-93. PubMed ID: 21220723
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Dealing with requests for pharmacological cognitive enhancement from healthy students.
    Chandramouleeswaran S; Edwin NC; Rajaleelan W
    Indian J Med Ethics; 2016; 1(3):196. PubMed ID: 27474703
    [TBL] [Abstract][Full Text] [Related]  

  • 46. The ethical role of neurologists in the AIDS epidemic. Report of the Ethics and Humanities Subcommittee of the American Academy of Neurology.
    Neurology; 1992 May; 42(5):1116-7. PubMed ID: 1579238
    [No Abstract]   [Full Text] [Related]  

  • 47. Pharmacological Neuroenhancement: Current Aspects of Categorization, Epidemiology, Pharmacology, Drug Development, Ethics, and Future Perspectives.
    Daubner J; Arshaad MI; Henseler C; Hescheler J; Ehninger D; Broich K; Rawashdeh O; Papazoglou A; Weiergräber M
    Neural Plast; 2021; 2021():8823383. PubMed ID: 33519929
    [TBL] [Abstract][Full Text] [Related]  

  • 48. The incredibles.
    Lawton G
    New Sci; 2006 May 13-19; 190(2551):32-8. PubMed ID: 17115500
    [No Abstract]   [Full Text] [Related]  

  • 49. Enhancing, not cheating.
    Nature; 2007 Nov; 450(7168):320. PubMed ID: 18004327
    [No Abstract]   [Full Text] [Related]  

  • 50. Drugs for enhancing cognition and their ethical implications: a hot new cup of tea.
    Cheshire WP
    Expert Rev Neurother; 2006 Mar; 6(3):263-6. PubMed ID: 16533129
    [No Abstract]   [Full Text] [Related]  

  • 51. [Neuroethics of pharmaceutical cognitive enhancement: the first ten years: current problems and practical guiding principles].
    Metzinger TK
    Fortschr Neurol Psychiatr; 2012 Jan; 80(1):36-43. PubMed ID: 22234814
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Enhancing cognition in the intellectually intact.
    Whitehouse PJ; Juengst E; Mehlman M; Murray TH
    Hastings Cent Rep; 1997; 27(3):14-22. PubMed ID: 9219019
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Lifestyle use of drugs by healthy people for enhancing cognition, creativity, motivation and pleasure.
    d'Angelo LC; Savulich G; Sahakian BJ
    Br J Pharmacol; 2017 Oct; 174(19):3257-3267. PubMed ID: 28427114
    [TBL] [Abstract][Full Text] [Related]  

  • 54. How does enhancing cognition affect human values? How does this translate into social responsibility?
    Cabrera LY
    Curr Top Behav Neurosci; 2015; 19():223-41. PubMed ID: 25048389
    [TBL] [Abstract][Full Text] [Related]  

  • 55. [Hippocampus: a target for cognition enhancers].
    Arushanian EB; Beĭer EV
    Eksp Klin Farmakol; 2007; 70(4):59-65. PubMed ID: 18078044
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Buddhism and neuroethics: the ethics of pharmaceutical cognitive enhancement.
    Fenton A
    Dev World Bioeth; 2009 Aug; 9(2):47-56. PubMed ID: 18312602
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Drugs can be used to treat more than disease.
    Bostrom N
    Nature; 2008 Jan; 451(7178):520. PubMed ID: 18235476
    [No Abstract]   [Full Text] [Related]  

  • 58. Cosmetic neurology: the role of healthcare professionals.
    Muhammed K
    Med Health Care Philos; 2014 May; 17(2):239-40. PubMed ID: 23775336
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Ultra-low exposure to α-7 nicotinic acetylcholine receptor partial agonists elicits an improvement in cognition that corresponds with an increase in α-7 receptor expression in rodents: implications for low dose clinical efficacy.
    Werkheiser JL; Sydserff S; Hubbs SJ; Ding M; Eisman MS; Perry D; Williams AJ; Smith JS; Mrzljak L; Maier DL
    Neuroscience; 2011 Jul; 186():76-87. PubMed ID: 21550383
    [TBL] [Abstract][Full Text] [Related]  

  • 60. [Therapeutic and cosmetic psychopharmacology. Risks and limits].
    Echarte Alonso LE
    Cuad Bioet; 2009; 20(69):211-30. PubMed ID: 19507923
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.